We are live on ! Find out more
LPCN icon

Lipocine
LPCN

47 hedge funds and large institutions have $119M invested in Lipocine in 2015 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 14 increasing their positions, 14 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,039% more call options, than puts

Call options by funds: $752K | Put options by funds: $66K

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

18% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 11

9% more capital invested

Capital invested by funds: $109M → $119M (+$9.44M)

4% more funds holding

Funds holding: 45 → 47 (+2)

0% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 14

Holders
47
Holders Change
+2
Holders Change %
+4.44%
% of All Funds
1.23%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.08%
New
13
Increased
14
Reduced
14
Closed
11
Calls
$752K
Puts
$66K
Net Calls
+$686K
Net Calls Change
+$686K

Top Buyers

1
CC
Carlson Capital
Texas
+$2.83M
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$1.41M
3
EI
EAM Investors
California
+$721K
4
OAM
Oxford Asset Management
United Kingdom
+$673K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$596K

Top Sellers

1
VM
VHCP Management
New York
-$5.18M
2
RA
Royce & Associates
New York
-$2.44M
3
TC
TFS Capital
Pennsylvania
-$2.04M
4
RCM
Rotella Capital Management
Washington
-$1.23M
5
LOAMU
Lombard Odier Asset Management (USA)
New York
-$1.05M
Name Holding Trade Value Shares
Change 		Change in
Stake
Invesco
1
Invesco
Georgia
$13.9M – – –
VAM
2
Visium Asset Management
New York
$12.6M – – –
VM
3
VHCP Management
New York
$11M -$5.18M -24,706 -33%
RA
4
Royce & Associates
New York
$10.6M -$2.44M -11,642 -19%
CAM
5
Cormorant Asset Management
Massachusetts
$8.62M – – –
GGHC
6
Gilder Gagnon Howe & Co
New York
$6.5M -$245K -1,166 -4%
VMI
7
VHCP Management II
New York
$5.43M +$5.18M +24,706 New
Vanguard Group
8
Vanguard Group
Pennsylvania
$5.38M +$302K +1,439 +6%
EI
9
EAM Investors
California
$5.2M +$721K +3,437 +17%
FCMI
10
Foresite Capital Management III
California
$4.27M +$4.07M +19,412 New
Dimensional Fund Advisors
11
Dimensional Fund Advisors
Texas
$3.51M +$1.41M +6,732 +73%
KCM
12
Kingdon Capital Management
New York
$3.15M -$631K -3,010 -17%
CC
13
Carlson Capital
Texas
$2.97M +$2.83M +13,512 New
BIT
14
BlackRock Institutional Trust
California
$2.87M -$173K -824 -6%
RI
15
RTW Investments
New York
$2.85M +$98.8K +471 +4%
Ameriprise
16
Ameriprise
Minnesota
$2.76M +$85.2K +406 +3%
LOAMU
17
Lombard Odier Asset Management (USA)
New York
$2.72M -$1.05M -5,010 -29%
Renaissance Technologies
18
Renaissance Technologies
New York
$2.32M -$747K -3,559 -25%
SM
19
Sabby Management
Florida
$1.97M -$607K -2,894 -24%
RFC
20
Russell Frank Company
Washington
$1.26M +$87.7K +418 +8%
Geode Capital Management
21
Geode Capital Management
Massachusetts
$1.15M +$1.26K +6 +0.1%
Allianz Asset Management
22
Allianz Asset Management
Germany
$1.03M -$49.1K -234 -5%
Bank of New York Mellon
23
Bank of New York Mellon
New York
$951K -$29.8K -142 -3%
OAM
24
Oxford Asset Management
United Kingdom
$699K +$673K +3,208 New
DCM
25
DAFNA Capital Management
California
$647K +$61.7K +294 +11%
1
2 3

LPCN Hedge Fund Activity: Q4 2015 in Review

47 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q4 2015, worth a combined $119M — up 8.6% from $109M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new LPCN positions and 11 closed out — a net gain of 2 holders — while 14 added to existing stakes and 14 trimmed.

The largest buyer was Carlson Capital, opening a new position worth an estimated $2.83M. The largest seller was VHCP Management, cutting an estimated $5.18M.

  • 47 institutional investors held Lipocine (LPCN) as of Q4 2015, up from 45 in Q3 2015.
  • Funds reported $119M of Lipocine stock for Q4 2015, up 8.6% quarter-over-quarter.
  • 13 funds opened new Lipocine positions in Q4 2015 and 11 closed out, a net change of +2 holders.
  • The largest Lipocine buyer in Q4 2015 was Carlson Capital, an estimated $2.83M added.
  • The largest Lipocine seller in Q4 2015 was VHCP Management, an estimated $5.18M sold.

Based on aggregated 13F filings for Q4 2015.